Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/26/2025 | $50.00 → $51.00 | Buy | H.C. Wainwright |
| 12/23/2024 | $50.00 | Buy | H.C. Wainwright |
| 5/20/2022 | $45.00 → $40.00 | Overweight | Cantor Fitzgerald |
| 6/30/2021 | $45.00 | Overweight | Cantor Fitzgerald |
Elizabeth Taylor Appointed Chief Financial Officer; Michael McNeil Appointed Chief Accounting Officer and Chief Administrative Officer FORT WORTH, TX, Jan. 21, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today the expansion of the Company's executive leadership team with new appointments. Elizabeth Taylor has been appointed to the position of Chief Financia
FORT WORTH, TX, April 05, 2024 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today the appointments of Jake Waldrop as Chief Operating Officer and Tyler Palmer as Chief Corporate Development and Strategy Officer. Zach Fleming, Sanara's Chief Executive Officer, stated, "Jake and Tyler are seasoned executives with a wealth of experience in the medical device and woun
FORT WORTH, TX, Dec. 28, 2021 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara" or the "Company") (NASDAQ:SMTI), a provider of products and technologies for surgical and chronic wound care dedicated to improving patient outcomes, announced today that Zachary ("Zach") B. Fleming has been appointed Chief Executive Officer effective January 1, 2022. Ron Nixon, Sanara's Executive Chairman, stated, "Zach is an outstanding leader who has been a driving force behind the development and execution of our surgical wound strategy. During his time as President of the Surgical Division, he has overseen double-digit year over year revenue growth of our business and steered the division through the ch
8-K - Sanara MedTech Inc. (0000714256) (Filer)
8-K - Sanara MedTech Inc. (0000714256) (Filer)
10-Q - Sanara MedTech Inc. (0000714256) (Filer)
4 - Sanara MedTech Inc. (0000714256) (Issuer)
4 - Sanara MedTech Inc. (0000714256) (Issuer)
4 - Sanara MedTech Inc. (0000714256) (Issuer)
Q1 Net Revenue Increased 26% Year-Over-Year FORT WORTH, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today reported its financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Summary ●Net revenue increased 26% to $23.4 million, compared to $18.5 million in the first quarter of 2024. ●Net loss of $3.5 million, compared to a net loss of $1.8 million in the first quar
FORT WORTH, TX, April 23, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," or the "Company") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced it will report its first quarter 2025 financial results on Wednesday, May 14, 2025 before the U.S. financial markets open. The Company will host a conference call and webcast on May 14, 2025 at 8:00 a.m. Eastern Time to discuss the results of the quarter ended March 31, 2025 and hold a question and answer session at the end of the call. The toll-fr
Q4 Net Revenue Increased 49% Year-Over-Year; 2024 Net Revenue Increased 33% Year-Over-Year FORT WORTH, TX, March 25, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter 2024 Financial Summary ●Net revenue increased 49% to $26.3 million, compared to $17.7 million in the fourth quarter of 2023. ●Net loss of
H.C. Wainwright reiterated coverage of Sanara MedTech with a rating of Buy and set a new price target of $51.00 from $50.00 previously
H.C. Wainwright initiated coverage of Smtek with a rating of Buy and set a new price target of $50.00
Cantor Fitzgerald resumed coverage of Smtek with a rating of Overweight and set a new price target of $40.00 from $45.00 previously
Q1 Net Revenue Increased 26% Year-Over-Year FORT WORTH, TX, May 14, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today reported its financial results for the first quarter ended March 31, 2025. First Quarter 2025 Financial Summary ●Net revenue increased 26% to $23.4 million, compared to $18.5 million in the first quarter of 2024. ●Net loss of $3.5 million, compared to a net loss of $1.8 million in the first quar
FORT WORTH, TX, April 23, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," or the "Company") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, today announced it will report its first quarter 2025 financial results on Wednesday, May 14, 2025 before the U.S. financial markets open. The Company will host a conference call and webcast on May 14, 2025 at 8:00 a.m. Eastern Time to discuss the results of the quarter ended March 31, 2025 and hold a question and answer session at the end of the call. The toll-fr
FORT WORTH, TX, April 10, 2025 (GLOBE NEWSWIRE) -- Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ:SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skincare markets, announced today that management will present at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub, which is being held at the Paris Hotel & Casino in Las Vegas, NV from April 22 – 25, 2025. Management will deliver a presentation to investors on Wednesday, April 23 at approximately 3:30 p.m. Pacific Time. The presentation m
SC 13G - Sanara MedTech Inc. (0000714256) (Subject)